Sustained-release implant promising for long-term IOP reduction
E. Randy Craven, MD, shares results from a phase 1/2 study involving an intracameral bimatoprost sustained-release implant.
E. Randy Craven, MD, discusses the pearls of his presentation, "Biodegradation of Intracameral Bimatoprost Sustained-Release Implant (Bimatoprost SR, Allergan) in a 24-Month, Phase 1/2 Study in Glaucoma Patients," which he shared at the annual 2019 ASCRS meeting in San Diego.
RELATED: Novel compound shows promise for dry eye in proof-of-concept study
Recent Videos
Related Content
